Tin tức & Cập nhật

Patients with heart failure and preserved ejection fraction (HFpEF) treated with dapagliflozin experienced improvements in symptoms and physical limitations, according to results of the PRESERVED-HF study presented at HFSA 2021.

Dual antiplatelet therapy (DAPT) with cilostazol performs better than either aspirin or clopidogrel alone at reducing the risk of recurrent stroke or vascular events without increasing the incidence of bleeding for patients with ischaemic stroke and intracranial arterial stenosis, according to the results of the CSPS.com* trial.

Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.

Monotherapy with ticagrelor after a month-long course of dual antiplatelet (DAPT) with ticagrelor plus aspirin works to reduce the risk of bleeding without compromising ischaemic outcomes among patients with acute coronary syndrome (ACS) as compared with guideline-recommended treatment with 12-month DAPT followed by aspirin monotherapy, according to data from the GLOBAL LEADERS trial.

Use of linaclotide results in a significant reduction in several abdominal symptoms, such as bloating, discomfort, and pain, among patients with constipation-predominant irritable bowel syndrome (IBS-C) as compared with placebo, according to a study. In addition, reported adverse events (AEs) are in line with the established safety profile.

Patients on sodium-glucose co-transporter (SGLT) 2 inhibitors are less likely to develop asthma compared with those on dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), a study has found.

New data presented at EADV 2021 support the efficacy of secukinumab 300-mg dose in a 2-mL autoinjector compared with two 150 mg in 1 mL pre-filled syringes or placebo for psoriasis, with no new safety signals observed within 52 weeks.

An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.